Form 4: BridgeBio Pharma Director Andrew Lo Sells 100,000 Shares

Director Andrew Lo sold 100,000 shares of BridgeBio Pharma (BBIO) on May 2, 2025, at an average price of $38.499 per share.

Summary

• On May 2, 2025, Andrew Lo, a director of BridgeBio Pharma, Inc. (BBIO), sold 100,000 shares of common stock.
• The sale was executed at a weighted average price of $38.499 per share, with individual prices ranging from $38.155 to $38.75.
• Following the transaction, Andrew Lo directly owns 48,099 shares and indirectly owns 105,583 shares through a joint tenancy with rights of survivorship (JTWROS) with Nancy N. Lo.
• The sale was reported on a Form 4 filing with the Securities and Exchange Commission (SEC).

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of an insider sale. The size of the sale is not significant enough to warrant a strong negative sentiment, and there's no indication of any specific negative event driving the sale.

Industry Context

This is a routine disclosure of an insider transaction. It's important to monitor insider activity as it can provide insights into management's perspective on the company's valuation and future prospects. However, one sale does not necessarily indicate a negative outlook.

Stakeholder Impact

• The sale of shares by a director could potentially create short-term uncertainty among shareholders.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Andrew Lo, stock sale, Form 4, director, insider trading, JTWROS